|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 239.00 USD | -2.57% |
|
-1.91% | +15.40% |
| 01:33am | US FDA approves Johnson & Johnson's blood cancer drug after speedy review | RE |
| 01:29am | Johnson & Johnson's Janssen Biotech Unit Secures US FDA Approval for Multiple Myeloma Treatment | MT |
Company Valuation: Johnson & Johnson
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 4,48,463 | 4,61,875 | 3,76,932 | 3,49,226 | 5,00,242 | 5,91,148 | - | - |
| Change | - | 2.99% | -18.39% | -7.35% | 43.24% | 18.17% | - | - |
| Enterprise Value (EV) 1 | 4,50,606 | 4,78,015 | 3,83,337 | 3,61,338 | 5,28,042 | 6,09,135 | 5,97,209 | 6,01,548 |
| Change | - | 6.08% | -19.81% | -5.74% | 46.14% | 15.36% | -1.96% | 0.73% |
| P/E ratio | 21.8x | 26.2x | 11.4x | 25.1x | 18.8x | 25x | 23.1x | 22.2x |
| PBR | 6.05x | 6.13x | 5.83x | 4.88x | 6.14x | 6.76x | 6x | 5.49x |
| PEG | - | -1.9x | 0x | -0.4x | 0.2x | -2.3x | 2.79x | 5.61x |
| Capitalization / Revenue | 4.78x | 4.86x | 4.43x | 3.93x | 5.31x | 5.88x | 5.57x | 5.25x |
| EV / Revenue | 4.81x | 5.03x | 4.5x | 4.07x | 5.61x | 6.05x | 5.63x | 5.34x |
| EV / EBITDA | 12.3x | 14.6x | 12.6x | 12.3x | 15.9x | 16.5x | 15.2x | 14.2x |
| EV / EBIT | 15.4x | 16x | 14x | 13.7x | 17.4x | 18.2x | 16.5x | 15.3x |
| EV / FCF | 22.8x | 27.8x | 21x | 18.2x | 26.8x | 24.2x | 22.7x | 20.7x |
| FCF Yield | 4.38% | 3.6% | 4.76% | 5.49% | 3.73% | 4.13% | 4.41% | 4.83% |
| Dividend per Share 2 | 4.19 | 4.45 | 4.7 | 4.91 | 5.14 | 5.299 | 5.598 | 5.737 |
| Rate of return | 2.46% | 2.52% | 3% | 3.39% | 2.48% | 2.16% | 2.28% | 2.34% |
| EPS 2 | 7.81 | 6.73 | 13.72 | 5.79 | 11.03 | 9.823 | 10.64 | 11.06 |
| Distribution rate | 53.6% | 66.1% | 34.3% | 84.8% | 46.6% | 53.9% | 52.6% | 51.9% |
| Net sales 1 | 93,775 | 94,943 | 85,159 | 88,821 | 94,193 | 1,00,616 | 1,06,127 | 1,12,631 |
| EBITDA 1 | 36,634 | 32,630 | 30,414 | 29,288 | 33,261 | 36,932 | 39,361 | 42,298 |
| EBIT 1 | 29,244 | 29,965 | 27,460 | 26,466 | 30,358 | 33,444 | 36,102 | 39,381 |
| Net income 1 | 20,878 | 17,941 | 35,153 | 14,066 | 26,804 | 23,635 | 25,199 | 26,574 |
| Net Debt 1 | 2,143 | 16,140 | 6,405 | 12,112 | 27,800 | 17,987 | 6,061 | 10,400 |
| Reference price 2 | 170.35 | 176.66 | 156.58 | 145.05 | 207.63 | 245.30 | 245.30 | 245.30 |
| Nbr of stocks (in thousands) | 26,32,597 | 26,14,484 | 24,07,279 | 24,07,623 | 24,09,295 | 24,09,899 | - | - |
| Announcement Date | 25/01/22 | 24/01/23 | 23/01/24 | 22/01/25 | 21/01/26 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 24.97x | 6.05x | 16.49x | 2.16% | 59TCr | |
| 29.49x | 11.11x | 22.31x | 0.66% | 90TCr | |
| 25.65x | 6.99x | 14.03x | 2.93% | 42TCr | |
| 19.12x | 4.71x | 11.64x | 2.8% | 37TCr | |
| 25.48x | 5.28x | 14.64x | 1.65% | 31TCr | |
| 22.17x | 5.97x | 14.72x | 2.69% | 31TCr | |
| 28.12x | 4.91x | 15.36x | 2.81% | 30TCr | |
| 25.52x | 6.45x | 11.47x | 2.65% | 20TCr | |
| 20.55x | 6.25x | 11.3x | 2.2% | 18TCr | |
| 11.6x | 4.21x | 8.71x | 4.39% | 17TCr | |
| Average | 23.27x | 6.19x | 14.07x | 2.49% | 37.54TCr | |
| Weighted average by Cap. | 24.82x | 7.02x | 15.86x | 2.13% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- JNJ Stock
- Valuation Johnson & Johnson
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition